Supriya Lifescience cash flow

Latest FY25
Cash from operations
₹165cr+45.3% on FY24
Capital spending
₹162cr+11.5% on FY24
Free cash flow
₹2.3cr−₹32.3 cr in FY24
Cash from financing
−₹8.2cr−₹22.4 cr in FY24
₹ crore except per share
Tap a line for its trendLast 12Mto Jun 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22Mar 2022
Adjustments to reconcile profit — non-cash items
—20.415.811.810.1
———3.14.2
—−7.9−10.0−9.5−7.1
Changes in working capital
—−33.130.5−23.5−19.8
—−22.7−27.030.5−41.7
—15.0−4.715.3−2.1
Cash from operating activities
268————
—16511366.248.8
—16511366.248.8
Cash from investing activities
—16214610859.9
———0.50.1
—0.00.0——
—9.610.6——
—−152−174−133−59.8
Cash from financing activities
—0.10.40.30.8
——4.84.84.4
—−8.2−22.4−3.4150
—4.2−82.6−70.3139
—75.015822889.3
Reference items
290————
33.2%————
2.32.3−32.3−42.3−11.1
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SUPRIYA₹869.30

Supriya Lifescience Ltd.

· Pharma & Health
₹ CrorePeersSTARSPARCTHYROCARESHILPAMEDVIYASHRUBICONYATHARTHPARKHOSPS
View
In ₹ Crore except Per Share
12 Months Ending
FY22
31/03/2022
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation10.111.815.820.4—
+ Finance Costs4.23.1———
+ Interest Income-7.1-9.5-10.0-7.9—
Changes in Working Capital
+ Inventories-19.8-23.530.5-33.1—
+ Trade Receivables — Current-41.730.5-27.0-22.7—
+ Trade Payables — Current-2.115.3-4.715.0—
Cash from Operating Activities
Profit Before Tax (per I/S)————268.2
Cash from Operations (pre-tax)48.866.2113.3164.7—
Cash from Operating Activities48.866.2113.3164.7—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)59.9108.4145.7162.4—
+ Disp of Fixed Assets0.10.5———
+ Dividends Received — Investing——0.00.0—
+ Interest Received — Investing——10.69.6—
Cash from Investing Activities-59.8-133.1-173.6-152.2—
Cash from Financing Activities
+ Payment of Lease Liabilities0.80.30.40.1—
+ Dividends Paid4.44.84.8——
Cash from Financing Activities149.7-3.4-22.4-8.2—
Net Changes in Cash138.6-70.3-82.64.2—
Closing Cash89.3227.9157.675.0—
Reference Items
EBITDA————289.8
EBITDA Margin %————33.21
Free Cash Flow (CFO − Capex)-11.1-42.3-32.32.32.3
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY25 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 89%.